Breakthrough Israeli Study: Effective Biological Treatment for Lung Cancer
Researchers at the Weizmann Institute of Science have discovered that the biological drug Erbitux may be effective in inhibiting the growth of lung cancer tumors with a specific EGFR gene mutation. In trials on lab mice, Erbitux prevented the tumors from growing, and the researchers plan to assess its effectiveness on lung cancer patients. The drug offers potential for personalized treatment and improved chances of success, particularly for patients with the L858R mutation. If clinical trials replicate the findings, Erbitux could be approved for use as a first-line treatment for this specific mutation, potentially saving lives.